These results indicate that metabolic reprogramming in HER2-positive cancer cells involves upregulation of genes involved in de novo lipogenesis, and targeting LXR with novel ligand 1E5 is a potential strategy for exploiting metabolic changes in tumor cells. The gene discussed is ERBB2; the disease is neoplasm.